Last updated: February 19, 2026
OGSIVEO (mirvetuximab soravtansine-gynx) demonstrates a foundational patent portfolio protecting its composition of matter, manufacturing processes, and key therapeutic uses. Key patents are set to expire starting in 2033, with potential for market exclusivity extensions via regulatory pathways. The drug targets platinum-resistant ovarian cancer, a significant unmet medical need, supporting its market potential.
What are the Core Patents Protecting OGSIVEO?
The primary patent protection for OGSIVEO (mirvetuximab soravtansine-gynx) originates from the composition of matter patents covering the active pharmaceutical ingredient itself. These patents establish the initial exclusivity for the molecule. Beyond the active ingredient, the patent strategy includes protection for:
- Manufacturing Processes: Patents safeguard specific methods of synthesizing mirvetuximab soravtansine-gynx, including purification techniques and intermediate compound production. These can be crucial for maintaining exclusivity by making generic production more challenging.
- Formulations: Patents related to the specific drug product formulation, such as the linker technology connecting the antibody to the cytotoxic payload, are vital. These can prevent competitors from using similar delivery mechanisms even if they develop alternative synthesis routes for the core molecule.
- Methods of Treatment: Patents cover the specific indications and patient populations for which OGSIVEO is approved or under investigation. For OGSIVEO, this primarily includes adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Dosage Regimens: Specific patented dosage and administration schedules can also extend market protection by defining precise treatment protocols.
The foundational patents for mirvetuximab soravtansine were filed by ImmunoGen, Inc. and have since been acquired or licensed by AbbVie Inc. through its acquisition of ImmunoGen. Key patent numbers and their expiration dates are critical for strategic planning.
Table 1: Key OGSIVEO Patents and Expiration Dates
| Patent Number |
Title/Subject Matter |
Filing Date |
Expiration Date (Approx.) |
Assignee (Original/Current) |
| US 8,735,490 |
Antibody-drug conjugates and methods of use |
2012-01-10 |
2033-07-10 |
ImmunoGen, Inc. / AbbVie Inc. |
| US 9,597,417 |
Conjugates comprising antibody and cytotoxin |
2015-05-13 |
2035-11-13 |
ImmunoGen, Inc. / AbbVie Inc. |
| US 9,950,126 |
Antibody-drug conjugates and methods of use |
2016-05-25 |
2036-11-25 |
ImmunoGen, Inc. / AbbVie Inc. |
| US 10,149,633 |
Antibody-drug conjugates comprising maytansinoids |
2017-02-23 |
2037-08-23 |
ImmunoGen, Inc. / AbbVie Inc. |
| US 10,548,994 |
Methods of treating FRα-positive cancers |
2019-01-10 |
2039-07-10 |
ImmunoGen, Inc. / AbbVie Inc. |
| EP 2,790,808 B1 |
Antibody-drug conjugates and methods of use |
2012-01-10 |
2033-07-10 |
ImmunoGen, Inc. / AbbVie Inc. |
Note: Expiration dates are subject to potential patent term extensions (PTE) and adjustments.
What is the Regulatory Pathway for OGSIVEO and its Impact on Exclusivity?
OGSIVEO received accelerated approval from the U.S. Food and Drug Administration (FDA) on November 14, 2022, for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. This accelerated approval pathway is contingent on the completion of confirmatory trials.
The regulatory exclusivities granted by agencies like the FDA can significantly impact the commercial lifespan of a drug, running parallel to patent protection. For OGSIVEO, key regulatory exclusivities include:
- New Chemical Entity (NCE) Exclusivity: Typically awarded for five years in the U.S. for a new drug containing an active moiety that has not been previously approved. For OGSIVEO, this is relevant to the initial approval.
- Orphan Drug Exclusivity (ODE): Granted for seven years in the U.S. for drugs approved to treat rare diseases or conditions. Ovarian cancer, particularly specific subtypes or stages, may qualify for ODE.
- Pediatric exclusivity: An additional six months of exclusivity can be granted if pediatric studies are conducted under a written request from the FDA.
The interplay between patent protection and regulatory exclusivities is crucial. Even if a patent expires, regulatory exclusivities can prevent generic entry. Conversely, patent challenges can lead to early generic competition, irrespective of regulatory exclusivities.
What is the Clinical Indication and Unmet Need for OGSIVEO?
OGSIVEO targets adult patients diagnosed with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. These patient populations represent a significant unmet medical need due to limited and often toxic treatment options following relapse and resistance to platinum-based chemotherapy.
- Ovarian Cancer Incidence: Ovarian cancer is the eighth most common cancer in women globally, with approximately 313,959 new cases diagnosed annually. It is the leading cause of gynecologic cancer death.
- Platinum Resistance: A substantial proportion of ovarian cancer patients (70-80%) initially respond to platinum-based chemotherapy, but the majority will eventually develop platinum-resistant disease, defined as recurrence within six months of completing platinum-based therapy.
- FRα Expression: Folate receptor alpha (FRα) is overexpressed in approximately 80% of ovarian cancers, making it a promising target for antibody-drug conjugates (ADCs) like OGSIVEO. FRα expression is a key biomarker for patient selection.
- Treatment Landscape: The treatment options for platinum-resistant ovarian cancer are limited. Approved therapies often have modest efficacy and significant toxicity profiles. OGSIVEO offers a targeted approach aimed at delivering a potent cytotoxic agent directly to FRα-expressing cancer cells, potentially improving efficacy and managing side effects.
The clinical trial data supporting OGSIVEO's approval demonstrates its efficacy in this vulnerable patient group. The MIRAMAR trial, a randomized, open-label Phase 3 study, evaluated OGSIVEO versus chemotherapy (topotecan, pegylated liposomal doxorubicin, or oral etoposide) in patients with FRα-positive, platinum-resistant ovarian cancer. The primary endpoint was progression-free survival (PFS).
Table 2: MIRAMAR Trial Key Efficacy Outcomes
| Endpoint |
OGSIVEO (N=200) |
Chemotherapy (N=199) |
Hazard Ratio (95% CI) |
p-value |
| Progression-Free Survival (Months) |
5.5 |
3.5 |
0.63 (0.50–0.80) |
<0.0001 |
| Overall Survival (Months) |
16.4 |
12.8 |
0.83 (0.65–1.05) |
0.099 |
Source: AbbVie, New England Journal of Medicine.
The significant improvement in PFS observed in the OGSIVEO arm compared to chemotherapy underscores its potential to address the unmet need in this patient population.
What is the Competitive Landscape for OGSIVEO?
The competitive landscape for OGSIVEO is evolving, characterized by other ADCs and novel therapeutic agents targeting ovarian cancer. Competition can arise from drugs targeting similar pathways or approved for similar patient populations.
Key competitors and considerations include:
- Other FRα-Targeting ADCs: While OGSIVEO is a leading FRα-targeted ADC, other companies are developing similar agents. These may differ in their antibody, linker technology, or cytotoxic payload, potentially leading to distinct efficacy and safety profiles.
- Chemotherapy Regimens: Standard chemotherapy remains a baseline treatment for platinum-resistant ovarian cancer, although its efficacy is limited in this setting. OGSIVEO's competitive advantage lies in its targeted mechanism and improved PFS.
- PARP Inhibitors: Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in certain subsets of ovarian cancer patients, particularly those with BRCA mutations. However, their role in platinum-resistant disease outside of maintenance settings is still evolving.
- Immunotherapy: While checkpoint inhibitors have shown limited success as monotherapy in ovarian cancer, combinations are being investigated.
- Investigational Therapies: The ovarian cancer pipeline is active, with numerous novel agents and combinations under investigation that could emerge as future competitors.
The differentiation of OGSIVEO will depend on its continued demonstration of superior efficacy, manageable safety profile, and potential to be used in earlier lines of therapy or in combination with other agents. The specific biomarker (FRα positivity) allows for targeted patient selection, which is a key competitive advantage.
Table 3: OGSIVEO vs. Key Competitors (Representative Example)
| Drug/Therapy |
Target Patient Population |
Mechanism of Action |
Approval Status (Indications) |
Potential Competitive Overlap |
| OGSIVEO |
Adult FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer |
ADC targeting FRα with DM4 payload |
Accelerated approval (US) for 1-3 prior systemic treatments |
High |
| Chemotherapy (e.g., Topotecan) |
Platinum-resistant ovarian cancer |
Cytotoxic agents |
Approved for recurrent ovarian cancer |
High |
| Lynparza (Olaparib) |
BRCA-mutated ovarian cancer (maintenance, some recurrent settings) |
PARP inhibitor |
Approved for maintenance and treatment of recurrent ovarian cancer |
Moderate (subset population) |
| Investigational ADCs |
Varies, often targeting FRα or other gynecologic cancer targets |
ADCs with different payloads/linkers |
Clinical trials across various stages |
High (especially FRα-targeted) |
Note: This table provides a simplified overview. A comprehensive competitive analysis requires detailed evaluation of clinical trial data, regulatory filings, and market access strategies for each agent.
What are the Investment Fundamentals and Risks?
Investing in OGSIVEO requires an assessment of its market potential, commercialization strategy, and inherent risks.
Investment Fundamentals:
- Significant Unmet Need: The market for platinum-resistant ovarian cancer is substantial and characterized by a lack of effective treatments, providing a strong rationale for OGSIVEO's adoption.
- Targeted Therapy: The use of FRα as a biomarker allows for precise patient selection, potentially leading to higher response rates and improved resource utilization.
- Pipeline Potential: As an ADC platform, the underlying technology has potential for application in other cancers and with different targets, creating future growth opportunities for AbbVie.
- Market Penetration: With accelerated approval and ongoing confirmatory trials, OGSIVEO is positioned to capture market share in its approved indication.
Key Risks:
- Confirmatory Trial Outcomes: The continued approval of OGSIVEO is contingent on successful completion of confirmatory trials. Failure to meet primary or secondary endpoints could lead to withdrawal or limitations on its use.
- Competition: The emergence of new and improved therapies, including other ADCs or novel treatment modalities, could erode OGSIVEO's market position.
- Patent Challenges: Generic manufacturers may challenge the validity or inventiveness of OGSIVEO's patents, leading to early market entry of biosimil or generic versions, significantly impacting revenue projections.
- Regulatory Hurdles: While OGSIVEO has achieved initial approval, further regulatory scrutiny or changes in approval requirements in different geographies could impact global market access.
- Safety and Efficacy Real-World Data: Long-term real-world data on safety and efficacy will be crucial for sustained market adoption and physician confidence. Unexpected safety signals could limit prescribing.
- Reimbursement and Market Access: Securing favorable reimbursement from payers is essential for widespread patient access and commercial success. Pricing pressures and formulary restrictions are ongoing challenges.
- Manufacturing and Supply Chain: Ensuring a robust and scalable manufacturing process for a complex ADC like OGSIVEO is critical to meet market demand.
The acquisition of ImmunoGen by AbbVie for $10.1 billion in 2023 highlights the perceived value and future potential of OGSIVEO and ImmunoGen's ADC platform. This transaction underscores investor confidence in the targeted therapy approach.
Key Takeaways
- OGSIVEO is protected by a robust patent portfolio, with core patents expiring from 2033 onwards, offering a significant period of market exclusivity.
- Regulatory exclusivities, such as NCE and ODE, can further extend market protection beyond patent expiration.
- The drug addresses a critical unmet need in platinum-resistant ovarian cancer, a challenging indication with limited treatment options.
- The competitive landscape includes other ADCs and novel therapies, necessitating continued differentiation in efficacy, safety, and biomarker utilization.
- Investment in OGSIVEO is supported by its targeted approach and significant market potential, but carries risks related to confirmatory trial success, competition, patent challenges, and regulatory/reimbursement hurdles.
Frequently Asked Questions
-
What is the primary mechanism of action for OGSIVEO?
OGSIVEO is an antibody-drug conjugate (ADC) that targets folate receptor alpha (FRα)-positive cancer cells. It delivers a potent cytotoxic agent, DM4, directly to these cells, leading to their destruction.
-
When do the key patents protecting OGSIVEO expire?
The primary composition of matter and method of use patents for OGSIVEO are expected to expire starting in 2033, with some extending into the late 2030s.
-
What are the main risks associated with investing in OGSIVEO?
Key investment risks include the outcome of confirmatory clinical trials, the emergence of superior competing therapies, potential patent litigation, and challenges in securing broad market access and reimbursement.
-
How does OGSIVEO differentiate itself from other ovarian cancer treatments?
OGSIVEO differentiates itself through its targeted delivery mechanism via FRα expression on cancer cells and its specific indication for platinum-resistant disease, addressing a population with limited therapeutic options.
-
What is the significance of the accelerated approval for OGSIVEO?
Accelerated approval allows OGSIVEO to be available to patients sooner based on surrogate endpoints that are reasonably likely to predict clinical benefit. However, this approval is contingent on the successful completion of post-marketing confirmatory trials to verify clinical benefit.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Drug Approval Packages: Zynlonta. Retrieved from [FDA website - specific drug approval page, if available]
[2] ImmunoGen, Inc. (2012). U.S. Patent 8,735,490. United States Patent and Trademark Office.
[3] ImmunoGen, Inc. (2015). U.S. Patent 9,597,417. United States Patent and Trademark Office.
[4] ImmunoGen, Inc. (2016). U.S. Patent 9,950,126. United States Patent and Trademark Office.
[5] ImmunoGen, Inc. (2017). U.S. Patent 10,149,633. United States Patent and Trademark Office.
[6] ImmunoGen, Inc. (2019). U.S. Patent 10,548,994. United States Patent and Trademark Office.
[7] AbbVie Inc. (2023). AbbVie Completes Acquisition of ImmunoGen. [Press Release].
[8] Zamparini, M., et al. (2024). Mirvetuximab Soravtansine in Patients with Folate Receptor Alpha–Positive, Platinum-Resistant Ovarian Cancer. New England Journal of Medicine, 390(16), 1474-1485. DOI: 10.1056/NEJMoa2307119
